ArticleWorld journal of surgical oncology2017
Dedifferentiated endometrioid carcinoma of the uterus : report of four cases and review of literature.
Article in World journal of surgical oncology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 24 citations in OpenAlex.
- Are micro-RNA 21 and 143 indicative as prognostic biomarkers in dedifferentiated endometrial adenocarcinoma?Molecular biology reports · 2024Article
- Undifferentiated endometrial carcinoma diagnosed during perimenopausal hormone therapy: a case report and literature review.Frontiers in oncology · 2024Article
- Dedifferentiated Endometrial Carcinoma: A Rare Aggressive Neoplasm-Clinical, Morphological and Immunohistochemical Features.Cancers · 2023Review
- Treatment and outcomes in undifferentiated and dedifferentiated endometrial carcinoma.Journal of gynecologic oncology · 2022Article
- Rare Subtype of Endometrial Cancer: Undifferentiated/Dedifferentiated Endometrial Carcinoma, from Genetic Aspects to Clinical Practice.International journal of molecular sciences · 2022Review
- Primary and Triage Cervical Screening Diagnostic Value of Methods for the Detection of Cervical Dysplasia.BioMed research international · 2022Article
- Dedifferentiated endometrioid adenocarcinoma of the uterus: A case series and review of literature.Gynecologic oncology reports · 2020Article
- [Un- and dedifferentiated endometrial carcinoma : A rare entity with a wide range of differential diagnosis].Der Pathologe · 2019Review
- Review
- Dedifferentiated Endometrial Carcinoma Could be A Target for Immune Checkpoint Inhibitors (Anti PD-1/PD-L1 Antibodies).International journal of molecular sciences · 2019Article
- Rapid progression of disease in two cases of undifferentiated endometrial carcinoma.Gynecologic oncology reports · 2019Article
- Two Cases of Dedifferentiated Endometrioid Carcinoma: Case Presentation and Brief Review of the Literature.Case reports in obstetrics and gynecology · 2018Article
- Dedifferentiated endometrial carcinoma: A report of three cases and review of the literature.Molecular and clinical oncology · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDedifferentiated endometrioid adenocarcinoma (DEAC) is rare and is known to be more aggressive than high-grade endometrioid carcinoma. Differentiating between the two is important to provide appropriate treatment for patients. CASE PRESENTATION: This is a retrospective study including four cases of DEAC of the uterus, which was diagnosed and treated in our Obstetrics and Gynecology department between January 2013 and December 2015. Clinical, pathological, and immunohistochemical staining features are discussed. Each tumor was composed of undifferentiated carcinoma (UC) and low-grade endometrioid carcinoma with abrupt transition between them. Two patients showed recurrence or progression within one month postoperatively and died at the last follow-up. An immunohistochemical study showed PAX-8, ER, PR, and E-cadherin expression in UC component.
conclusionsDEAC should not be underdiagnosed as conventional endometrioid adenocarcinoma due to its fulminant clinical course. Therefore, UC, including DEAC, should be further categorized to provide intensive treatment to improve patient survival.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.